|
[1]
|
Wright EM,Hirayama BA,Loo DF.Active sugar transport in health and disease[J].Intern Med,2007,261:32. |
|
[2]
|
Kanai Y,Lee WS,You G,et al.The human kidney low affinity Na/glucose cotransporter SGLT2: delineation of the major renal reabsorptive mechanism for D-glucose[J].Clin Investig,1994,93:397. |
|
[3]
|
Van den Heuvel LP,Assink K,Willemsen M,et al.Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2) [J].Hum Genet,2002,111:544. |
|
[4]
|
Calado J,Soto K,Clemente C,et al.Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria[J].Hum Genet,2004, 114:314. |
|
[5]
|
Pajor A,Wright EM.Cloning and functional expression of a mammalian Na+/nucleoside cotransporter. A member of the SGLT family[J].Biol Chem,1992,267:3557. |
|
[6]
|
Wright EM.Renal Na+-glucose cotransporters[J].Am J Physiol,2001,280:F10. |
|
[7]
|
Turk E,Zabel B,Mundlos S,et al.Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter[J].Nature,1991,350:354. |
|
[8]
|
Pajor AM,Randolph KM,Kerner SA,et al.Inhibitor binding in the human renal low-and high-affinity Na+/glucose cotransporters[J].J Pharmacol Exp Ther,2008,324:985. |
|
[9]
|
Ehrenkranz JRL,Lewis NG,Kahn CR,et al.Phlorizin: a review[J].Diabetes Metab Res Rev,2005,21:31. |
|
[10]
|
Oku A,Ueta K,Arakawa K,et al.T-1095, an inhibitor of renal Na+- glucose cotransporters, may provide a novel approach to treating diabetes[J].Diabetes,1999, 48:1794. |
|
[11]
|
Adachi T,Yasuda K,Okamoto Y,et al.T-1095, renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin induced diabetic rats[J].Metabolism,2000,49:990. |
|
[12]
|
Katsuno K,Fujimori Y,Takemura Y,et al.Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level[J].Pharmacol Exp Ther,2007,320:323. |
|
[13]
|
Hussey EK,Clark RV,Amin DM,et al.Early clinical studies to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus[J].Diabetes,2007,56 (Suppl 1):189. |
|
[14]
|
Fujimori Y,Katsuno K,Nakashima I,et al.Remogliflozin etabonate, in a novel category of selective low-affinity/high-capacity sodium glucose cotransporter (SGLT-2) inhibitors, exhibits antidiabetic efficacy in rodent models[J].Pharmacol Exp Ther,2008,327:268. |
|
[15]
|
Wei M,Bruce AE,Alexandra AN,et al.Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes[J].J Med Chem,2008,51(5):1145. |
|
[16]
|
Komoroski B,Vachharajani N,Boulton D,et al.Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects[J].Clin Pharmacol Ther,2009,85:520. |
|
[17]
|
Komoroski B,Vachharajani N,Feng Y,et al.Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus[J].Clin Pharmacol Ther,2009,85:513. |
|
[18]
|
List JF,Woo V,Morales E,et al.Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes mellitus[J].Diabetes Care,2009,32:650. |
|
[19]
|
Calado J,Loeffler J,Sakalliouglu O,et al.Familial renal glucosuria: SGLC5A2 mutation analysis and evidence of salt-wasting[J].Kidney Int,2006,69:852. |
点击查看大图
下载:
